论文部分内容阅读
抗乙型肝炎核心抗原的抗体(抗—HBc)检测,系证明乙型肝炎病毒复制的较好指标,它比检测乙型肝炎表面抗原(HBsAg)或其抗体(抗—HBs)更有价值。为此,作者检测了原发性肝癌患者的抗—HBc,藉以探讨肝癌与肝炎之间的关系。所用乙型肝炎核心抗原(HBcAg)均从HBsAg阳性的慢性肝炎患者的肝脏中提取。经电子显微镜观察,此类肝活检标本的肝细胞核内有很多27～29毫微米颗粒。用此提取的HBcAg作为抗原,以对流免疫电泳法和免疫扩散法来检测所有原发性肝癌及对照者的抗—HBc。结果三个地区的153例原发性肝癌患者中检出114例的抗—HBc,总的平均阳性率达75％,远较238例对照者的抗—HBc检出率(2.8％)高。因此,本文
Antibodies against hepatitis B core antigen (anti-HBc) test, the certificate of hepatitis B virus replication is a better indicator, it is more than the detection of hepatitis B surface antigen (HBsAg) or its antibodies (anti-HBs) more valuable. To this end, the authors tested anti-HBc in patients with primary liver cancer to explore the relationship between liver cancer and hepatitis. The hepatitis B core antigen (HBcAg) used was extracted from the liver of HBsAg-positive chronic hepatitis patients. Observed by electron microscopy, liver biopsy specimens of this liver cell nucleus has a lot of 27-29 nm particles. Using this extracted HBcAg as an antigen, all primary liver cancer and control subjects were tested for anti-HBc by convective immuno-electrophoresis and immunodiffusion. Results Of the 153 patients with primary liver cancer in the three regions, 114 cases of anti-HBc were detected, with a total average positive rate of 75% and far higher anti-HBc detection rate (2.8%) than that of 238 controls. Therefore, this article